glatiramer acetate
Selected indexed studies
- Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation. (Cells, 2022) [PMID:35563884]
- Glatiramer Acetate: from Bench to Bed and Back. (Isr Med Assoc J, 2019) [PMID:30905097]
- Glatiramer acetate: A complex drug beyond biologics. (Eur J Pharm Sci, 2019) [PMID:30902653]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation. (2022) pubmed
- Glatiramer Acetate: from Bench to Bed and Back. (2019) pubmed
- Glatiramer acetate: A complex drug beyond biologics. (2019) pubmed
- Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First-Generation Therapy to Elucidation of Immunomodulation and Repair. (2024) pubmed
- Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review. (2015) pubmed
- Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis. (2002) pubmed
- The Evolving Mechanisms of Action of Glatiramer Acetate. (2019) pubmed
- Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis. (2015) pubmed
- Anaphylaxis and glatiramer acetate. (2025) pubmed
- Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. (2005) pubmed